28 results on '"Rossi, Antonella Russo"'
Search Results
2. Age influences initial dose and compliance to imatinib in chronic myeloid leukemia elderly patients but concomitant comorbidities appear to influence overall and event-free survival
3. CD3+/Tregs Ratio in Donor Grafts Is Linked to Acute Graft-versus-Host Disease and Immunologic Recovery after Allogeneic Peripheral Blood Stem Cell Transplantation
4. Health-related quality of life in chronic myeloid leukemia patients receiving long-term therapy with imatinib compared with the general population
5. Recovery of CMV-Specific CD8 + T Cells and Tregs after Allogeneic Peripheral Blood Stem Cell Transplantation
6. Dasatinib is safe and effective in unselected chronic myeloid leukaemia elderly patients resistant/intolerant to imatinib
7. Establishing a National Network of Laboratories Using Next Generation Amplicon Deep Sequencing for BCR-ABL1 Kinase Domain Mutation Screening in Philadelphia Chromosome-Positive Leukemias: the ‘NEXT-IN-CML' Study
8. Long-Term Outcome Of Higher-Risk MDS Patients Treated With Azacitidine: Single Centre Experience
9. 4-Year Outcome Of 215 Patients With Newly Diagnosed Chronic Myeloid Leukemia (CML) Treated Frontline With Nilotinib In Investigator-Sponsored Studies. A Report From The Gimema CML Working Party
10. Impact of CD3/T Regs Ratio in Donor Graft On Survival Rates in Allogeneic Peripheral Blood Stem Cell Transplantation
11. Chronic Myeloid Leukemia with Variant t(9;22) Shows Dysregulated Expression of Genes Included in Pivotal Cellular Pathways
12. Moderate/ Severe Pleural Effusion As a Side Effect in Very Old Chronic Myeloid Leukemia (CML) Patients Undergoing Imatinib Treatment
13. Imatinib in Very Elderly (> 75 years) CML Patients: Are Low-Doses (
14. Age Influences Initial Dose and Compliance to Imatinib In Chronic Myeloid Leukemia Elederly Patients but Concomitant Comorbidities Appear to Influence Overall and Event-Free Survival
15. APPLICATION of EUTOS SCORE IN CHRONIC Myeloid LEUKEMIA AFFECTING VERY Elderly (>75 years) PATIENTS
16. Investigating Personal and Treatment Related Factors Associated with Adherence Behavior in Patients with Chronic Myeloid Leukemia Receiving Long Term Imatinib Therapy
17. Hammersmith Score Is Able to Identify Chronic Myeloid Leukemia Patients with Poor Prognosis Before Treatment with Second-Generation TKIs.
18. Low-Dose Dasatinib as Front-Line Therapy for Elderly (> 60 Years) Patients with CML
19. Outcome of Patients with CML Treated with Dasatinib or Nilotinib after Failure of Second Prior TKIs
20. Health-Related Quality of Life In Patients with Chronic Myeloid Leukemia Undergoing First Line Treatment with Imatinib for at Least Three Years Compared with the General Population. A Multicenter Study Including 448 Patients
21. Imatinib In Very Elderly CML Patients: What Can We Achieve?.
22. T/NK Lymphocytosis in CML Ph+ Patients During Dasatinib Therapy.
23. Real-Life Analysis of Dasatinib in Chronic Phase CML Patients Aged > 60 Years Resistant/Intolerant to Imatinib.
24. BCR-ABL Derived Peptide Vaccine in Chronic Myeloid Leukemia Patients with Molecular Minimal Residual Disease During Imatinib: Interim Analysis of a Phase 2 Multicenter GIMEMA CML Working Party Trial.
25. CXCR4 as a Predictor of Response in Acute Myeloid Leukemia
26. Chronic Myeloid Leukemia with Deletions on Der(9) Shows Mir-199b Downregulated Expression.
27. Unfavourable Outcome and Heterogeneity of Partner Chromosomes in Chronic Lymphocytic Leukemia with 14q32/IGH Translocations.
28. MicroRNAs as the Target of Deletions on der(9) in Chronic Myeloid Leukemia.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.